Venaxis selling 8,335,000 common stock shares to raise $18.4M to advance APPY1 Test in U.S.

Venaxis selling 8,335,000 common stock shares to raise $18.4M to advance APPY1 Test in U.S.

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE-Marked Appy1 Test, announced a $2.40-per-share pricing... Read More

By: InnovatioNews Friday April 4, 2014 0 comments Tags: APPY1, Castle Rock, FDA, Venaxis

Venaxis closes public stock offering, raises $14.4 million for APPY1

Venaxis closes public stock offering, raises $14.4 million for APPY1

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY) announced it has closed its underwritten public offering that resulted in the sale of 11.5 million shares of common stock and gross proceeds of $14.4... Read More

By: Steve Friday May 31, 2013 0 comments Tags: APPY1, Castle Rock, Steve Lundy, Venaxis

Venaxis expands European distribution network for APPY1 appendicitis test

Venaxis expands European distribution network for APPY1 appendicitis test

CASTLE ROCK - Venaxis Inc . (Nasdaq: APPY), an in vitro diagnostic company focused on gaining FDA approval and commercialization of its APPY1 appendicitis test, announced it has signed... Read More

By: Steve Tuesday March 19, 2013 0 comments Tags: APPY1, Castle Rock, Don Hurd, EMELCA Bioscience, Venaxis

Venaxis signs agreement with European distributor, gets first APPY1 order

Venaxis signs agreement with European distributor, gets first APPY1 order

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA approval for its blood-based appendicitis test, announced it has signed its first European... Read More

By: Steve Thursday February 14, 2013 0 comments Tags: APPY1, Castle Rock, Don Hurd, EMELCA Bioscience, Venaxis

Venaxis obtains CE Mark for APPY1 appendicitis test

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY), an in-vitro diagnostic company, has fulfilled the requirements for CE Marking in Europe for its APPY1 blood-based appendicitis test, the company announced.... Read More

By: Steve Tuesday January 8, 2013 0 comments Tags: APPY1, Castle Rock, CE Mark, Steve Lundy, Venaxis